Étiquette : phytocannabinoïdes

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al.,

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite

Clinicians’ Guide to Cannabidiol and Hemp Oils, Harrison J. VanDolah et al., 2019

Clinicians’ Guide to Cannabidiol and Hemp Oils Harrison J. VanDolah, Brent A. Bauer, and Karen F. Mauck  Mayo Clinic Proceedings, 2019, 94, (9), 1840-1851 https://doi.org/10.1016/j.mayocp.2019.01.003   Abstract Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the US Food and Drug Administration for treatment of rare, severe epilepsy, further putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and [...]

Lire la suite

Retrouvez l’ensemble des interventions des 24es Rencontres du RESPADD – GRECC : Utilisation cliniques des cannabinoïdes, juin 2019

Retrouvez l’ensemble des interventions des 24es Rencontres du RESPADD - GRECC : Utilisation cliniques des cannabinoïdes, juin 2019 Sarah LEJCZAK "Utilisation du Marinol en France : enquête auprès des prescripteurs" Roland TUBIANA et Fabienne CABY "Infection VIH et cannabinoïdes, état des lieux et pistes en recherche clinique" Allison McKIM : "Addicted to rehab : race, gender and drugs in the era of mass incarceration" Fabrice Olivet : "Races et drogues, les termes du sujet" François BAILLY : "Le cannabidiol en traitement "anti-addictif" chez les patients alcooliques : l'étude Caramel" Julien AZUAR "Usage de CBD et maladie psychiatrique" Pierre CHAMPY : "Cannabis sativa, plante médicinale en France ?" Jean-Michel [...]

Lire la suite

Cannabidiol for the Treatment of Drug Use Disorders, R.G. dos SANTOS, J.E.C. HALLAK, W. ZUARDI, J.A. de SOUZA, 2017

Chapter 97 - Cannabidiol for the Treatment of Drug Use Disorders R.G. dos SANTOS, J.E.C. HALLAK, W. ZUARDI, J.A. de SOUZA in "Handbook of Cannabis and Related Pathologies". "Biology, Pharmacology, Diagnosis, and Treatment", 2017, Pages 939-946 https://doi.org/10.1016/B978-0-12-800756-3.00113-7 Abstract The problematic use of psychoactive substances like alcohol, cannabis, cocaine, amphetamines, heroin, and nicotine carry a series of health, economic, and social costs to individuals and society. Although pharmacological treatments for alcohol, heroin, and nicotine abuse or dependence are available, there is no approved medication for the treatment of cannabis and stimulant dependence. Cannabidiol (CBD), a nonpsychotomimetic cannabinoid present in the cannabis plant, has anxiolytic, antipsychotic, antiepileptic, [...]

Lire la suite

Molecular Targets of the Phytocannabinoids-A Complex Picture, Paula Morales et al., 2017

Molecular Targets of the Phytocannabinoids-A Complex Picture Paula Morales, Dow P. Hurst, Patricia H. Reggio Progress in the Chemistry of Organic Natural Products, 2017 ; 103: 103–131. doi:10.1007/978-3-319-45541-9_4. 1 Introduction For centuries, hashish and marihuana, both derived from the Indian hemp Cannabis sativa L., have been used for their medicinal, as well as, their psychotropic effects. Phytocannabinoids are oxygen containing C21 aromatic hydrocarbons found in Cannabis sativa L. To date, over 120 phytocannabinoids have been isolated from Cannabis, including two compounds, (−)-trans-Δ9-tetrahydrocannabinol (Δ9-THC) and (−)-trans-Δ8-THC (Δ8-THC) that have been shown to bind to cannabinoid receptors and elicit the characteristic psychotropic effect associated with Cannabis [1]. [...]

Lire la suite

Molecular Pharmacology of Phytocannabinoids, Sarah E. Turner et al., 2017

Molecular Pharmacology of Phytocannabinoids Sarah E. Turner, Claire M. Williams, Leslie Iversen, and Benjamin J. Whalley © Springer International Publishing Switzerland 2017 A.D. Kinghorn, H. Falk, S. Gibbons, J. Kobayashi (eds.), Phytocannabinoids, Progress in the Chemistry of Organic Natural Products 103, 61-100. DOI 10.1007/978-3-319-45541-9_3 Contents 1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [...]

Lire la suite

A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products, Qingfang Meng et al., 2018

A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products Qingfang Meng, Beth Buchanan, Jonathan Zuccolo, Mathieu-Marc Poulin, Joseph Gabriele, David Charles Baranowski PLoS ONE, 2018, 13, 5, e0196396. https://doi.org/10.1371/journal.pone.0196396   Abstract In the past 50 years, Cannabis sativa (C. sativa) has gone from a substance essentially prohibited worldwide to one that is gaining acceptance both culturally and legally in many countries for medicinal and recreational use. As additional jurisdictions legalize Cannabis products and the variety and complexity of these products surpass the classical dried plant material, appropriate methods for measuring the biologically active constituents is paramount to ensure [...]

Lire la suite

Cannabinoids and Neuropathic Pain, P.W. Brownjohn and J.C. Ashton, 2012

Cannabinol and Neuropathic Pain P.W. Brownjohn and J.C. Ashton Neuropathic Pain, 2012, chap. 4, 79-102   1. Introduction Cannabinoids are drugs that are either derived from cannabis or that induce similar behavioural and physiological effects to cannabis. They fall into three classes: those that are produced by plants of the Cannabis genus, termed phytocannabinoids (plant cannabinoids); those that are produced within the body, termed endocannabinoids (endogenous cannabinoids); and those that are produced synthetically to mimic the pharmacology of naturally occurring cannabinoids. Cannabinoids stand in relation to cannabis as opioids such as codeine, pethidine, fentanyl, and methadone stand in relation to opium. While opium and opioids [...]

Lire la suite

A Review of Cannabis in Chronic Kidney Disease Symptom Management, Claudia Ho et al., 2019

A Review of Cannabis in Chronic Kidney Disease Symptom Management Claudia Ho, Dan Martinusen, and Clifford Lo2,4,5 Canadian Journal of Kidney Health and Disease, 2019, Volume 6, 1–14 DOI: 10.1177/2054358119828391 journals.sagepub.com/home/cjk Abstract Purpose of Review : Physical and psychological symptom burden in patients with advanced chronic kidney disease (CKD) is significantly debilitating; yet, it is often inadequately treated. Legalization of cannabis in Canada may attract increasing interest from patients for its medical use in refractory symptom management, but its indications and long-term adverse health impacts are poorly established, creating a challenge for clinicians to support its use. In this review, we summarize key clinical studies and [...]

Lire la suite

Cannabinoids : potential antitumoral agents ?, Manuel Guzmán, 2006

Cannabinoids: potential antitumoral agents ? Manuel Guzmán Cannabinoids, 2006, 1, 2, 15-17 © International Association for Cannabis as Medicine Mini-review Abstract Cannabinoids, the active components of Cannabis sativa L., act in the body by mimicking endogenous substances - the endocannabinoids - that activate specific cell surface receptors. Cannabinoids exert palliative effects in cancer patients. For example, they inhibit chemotherapy-induced nausea and vomiting, stimulate appetite and inhibit pain. In addition, cannabinoids inhibit tumor growth in laboratory animals. They do so by modulating key cell signaling pathways, thereby inducing antitumoral actions such as the apoptotic death of tumor cells as well as the inhibition of tumor angiogenesis. Of [...]

Lire la suite